Rein Therapeutics Inc. (RNTX)
NASDAQ: RNTX · Real-Time Price · USD
1.795
-0.115 (-6.02%)
Apr 28, 2025, 4:00 PM EDT - Market closed

Rein Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-62.88-15.73-27.33-26.16-21.16
Upgrade
Depreciation & Amortization
0.060.120.170.120.16
Upgrade
Loss (Gain) From Sale of Assets
--0.04--0.07-0.09
Upgrade
Asset Writedown & Restructuring Costs
37----
Upgrade
Loss (Gain) From Sale of Investments
-0.03-0.210.24-0.01
Upgrade
Stock-Based Compensation
1.121.192.082.261.89
Upgrade
Other Operating Activities
----0.39-
Upgrade
Change in Accounts Payable
-0.28-4.980.51-0.390.12
Upgrade
Change in Other Net Operating Assets
4.25-0.4-0.090.63-1.4
Upgrade
Operating Cash Flow
-22.29-19.81-24.87-23.75-20.48
Upgrade
Capital Expenditures
----0.16-0.01
Upgrade
Sale of Property, Plant & Equipment
-0.04-0.070.21
Upgrade
Cash Acquisitions
--0.1---
Upgrade
Investment in Securities
-16.2526.46-35.836.21
Upgrade
Investing Cash Flow
-16.226.46-35.926.41
Upgrade
Long-Term Debt Issued
-15.79--0.39
Upgrade
Net Debt Issued (Repaid)
-15.79--0.39
Upgrade
Issuance of Common Stock
10.79--59.1615.41
Upgrade
Other Financing Activities
7.03---3.51-
Upgrade
Financing Cash Flow
17.8215.79-55.6615.8
Upgrade
Foreign Exchange Rate Adjustments
--0.06---
Upgrade
Net Cash Flow
-4.4712.121.59-4.011.74
Upgrade
Free Cash Flow
-22.29-19.81-24.87-23.91-20.48
Upgrade
Free Cash Flow Per Share
-1.24-4.31-5.48-5.38-11.75
Upgrade
Levered Free Cash Flow
-14.82-7.62-14.48-13.5-13.61
Upgrade
Unlevered Free Cash Flow
-14.82-7.62-14.48-13.5-13.61
Upgrade
Change in Net Working Capital
-1.57-0.66-0.55-0.92.85
Upgrade
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q